Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the indole and urea chemical classes. It is an experimental molecule, not approved for clinical use, and has primarily been studied as a research tool. The structure features an indolinone core with a pyrrole substituent and a urea moiety. Literature links this scaffold to the inhibition of protein kinases, specifically phosphoinositide-dependent kinase 1 (PDK1), suggesting its mechanism of action may involve kinase inhibition[8]. However, there are no approved therapeutic indications or marketed products containing this compound[3][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-{2-oxo-3-[(1R)-1-(1H-pyrrol-2-yl)ethyl]-2H-indol-5-yl}urea.